Elanco Animal Health Stock Price, News & Analysis

Elanco Animal Health (NYSE: ELAN) is set to announce its third quarter 2021 financial results on November 5, 2021. A conference call will follow at 8:00 a.m. eastern time to discuss the company's performance, accessible via a live webcast on Elanco's website. The company specializes in products and services aimed at preventing and treating diseases in farm animals and pets, emphasizing sustainability and community impact. With nearly 70 years of experience in animal health, Elanco aims to improve the welfare of animals globally.

Elanco Animal Health (NYSE: ELAN) announces the appointment of Ellen de Brabander, Ph.D., as the new executive vice president of Innovation and Regulatory Affairs, effective October 18. She brings extensive experience, including leading the development of NexGard. The company maintains its innovation revenue expectations of $600 to $700 million by 2025, driven by the acquisition of KindredBio and ongoing pipeline advancements. Additionally, Aaron Schacht will lead the carve-out of Elanco's microbiome R&D platform to establish an independent biopharmaceutical entity.

Elanco Animal Health has completed the acquisition of Kindred Biosciences for $444 million, enhancing its position in the dermatology market. This acquisition is expected to bring three potential blockbusters by 2025 and add $100 million to Elanco's innovation revenue, totaling $600-$700 million. The partnership is poised to boost Elanco's annual revenue growth by 1% starting in 2024 and improve gross margins. This strategic move strengthens Elanco's commitment to addressing unmet medical needs for pets.

Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021. CEO Jeff Simmons will join a virtual fireside chat at 3:30 p.m. ET. Investors can access a live audio webcast on Elanco's investor website, with a replay available for 90 days.

Elanco is a leader in animal health, focusing on innovative solutions for the well-being of farm animals and pets. With nearly 70 years of experience, they aim to enhance animal health and contribute positively to communities worldwide.

Elanco Animal Health (NYSE: ELAN) reported robust Q2 2021 results, highlighting revenue of $1,279 million, exceeding guidance by $39 million, and a reported net loss of $210 million. This marks a 118% increase in revenue year-over-year, largely due to the acquisition of Bayer Animal Health. Adjusted EPS rose to $0.28, outperforming guidance, while adjusted EBITDA reached $291 million. The company raised its full-year revenue guidance for the third time in 2021, reflecting confidence in continued growth. Concerns include a subpoena from the SEC related to inventory practices and operational impacts from pandemic challenges.